NSTE-ACS (NSTEMI and UA)

2

Review clinical trials related to NSTE-ACS (NSTEMI and UA). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

"Discovery2" Study of Using MCG at Emergency Departments

The purpose of this research is to collect the magnetic signals from the heart to identify features that may help Emergency Department (ED) doctors differentiate high and low risk patients for heart related chest pain.

Participants needed: 200
Trial details
Age: 22+Biological sex: AllType: ObservationalSponsor: SB Technology, Inc.Updated: Sep 16, 2026Locations: 1
Eligibility criteria

Women and men aged 22 years and older [+4]

Unable to provide informed consent [+12]

Status: Not yet recruiting

Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)

This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD). NSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form: Intervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing). Control group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.

Participants needed: 1,904
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: RenJi HospitalUpdated: Jan 30, 2026
Eligibility criteria

Age: 18 years or older. [+4]

Have received thrombolytic treatment. [+11]